Home›Trial›NCT06402331
🔬NCT06402331Phase 2ACTIVE NOT RECRUITING

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Study Summary

This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I\&T). Patient population is adult participants with PSMA positive mCRPC who have had previous treatment with with 177Lu-PSMA-617 or another 177Lu-PSMA radioconjugate (RC). The purpose of the study is to determine the safety and tolerability, and recommended dose and regiment of FPI-2265.

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions / Drugs
FPI-2265
View on ClinicalTrials.gov ↗
Sponsor
FUSN
Fusion Pharmaceuticals
Oncology
D40/100
Study Details
Enrollment110 participants
Primary Completion—
Lead SponsorFusion Pharmaceuticals Inc.
Data Retrieved2026-04-11 04:14:16.520109+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.